RxDoctor Payments Data

Natalie Achamallah, MD

Critical Care Medicine · Santa Barbara, CANPI 1255881546

Payments from drug & device makers

$13,271in general payments, 2019–2025

Across 108 payments — averaging $122.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • GSK$749
  • Inari Medical, Inc.$743
  • United Therapeutics Corporation$673
  • Regeneron Healthcare Solutions, Inc.$556
  • AstraZeneca$551
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$290%
  • Travel & lodging$4794%
  • Food & beverage$6,50249%
  • Education$6,26147%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,271 in reported general payments places this provider in the 85th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$148,375
Medicare patients
331
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate12$151,723
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$52,973
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,926
SymbicortBudesonide/Formoterol Fumarate24$8,260
Mycophenolic AcidMycophenolate Sodium11$2,419
Wixela InhubFluticasone Propion/Salmeterol17$1,739
Albuterol Sulfate HfaAlbuterol Sulfate35$1,061
Montelukast Sodium66$528
Fluticasone Propionate19$261
Prednisone12$17
Amlodipine Besylate11$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$334$151,72312 claims
GSKTrelegy Ellipta, Anoro Ellipta$749$61,90078 claims
AstraZenecaSymbicort$551$8,26024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →